CMPX
$5.41-0.00 (-0.09%)
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bisp...
Recent News
What Compass Therapeutics (CMPX)'s Pipeline Progress And 2025 Losses Reveal About Its Oncology Strategy
Compass Therapeutics reported a fourth-quarter 2025 net loss of US$15.72 million and a full-year 2025 net loss of US$66.49 million, while advancing multiple oncology programs including the Phase 2/3 COMPANION-002 study of tovecimig and securing FDA clearance for CTX-10726. Investor attention has centered on the upcoming survival data from COMPANION-002 and the broadening pipeline, as new trial cohorts open and funding is expected to support operations into 2028. Next, we’ll examine how the...
Assessing Compass Therapeutics (CMPX) Valuation As CTX-009 Gains Attention In Biliary Tract Cancer Market
Compass Therapeutics (CMPX) is back on investors’ radar after fresh analysis of the biliary tract cancer market highlighted its lead candidate CTX-009 as a key emerging therapy in this growing treatment area. See our latest analysis for Compass Therapeutics. The latest focus on CTX-009 comes after a period where Compass Therapeutics’ share price has been choppy in the short term, with a 30 day share price return of an 11.25% decline, but underpinned by stronger momentum over longer horizons,...
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Ekso Bionics (EKSO) have performed compared to their sector so far this year.
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 113.7% in Compass Therapeutics, Inc. (CMPX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.